247 filings
Page 6 of 13
8-K
nvwdi5qnpss2 1l
17 Apr 18
NewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster Presentation
12:00am
8-K
6dbeu17csjazuov77xl8
16 Apr 18
Departure of Directors or Certain Officers
12:00am
8-K
0nncpg6szllpu
6 Apr 18
NewLink Genetics Announces Review of Clinical Programs
12:00am
8-K
14b3q2ie 2kin6
21 Mar 18
NewLink Genetics Appoints Chad A. Johnson to Board of Directors
12:00am
8-K
zn9emj7rdnty6jyoey
15 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K
o1054 ar1rtc9
14 Mar 18
NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
12:00am
8-K
h330id08jro 5h8b98k
13 Mar 18
Entry into a Material Definitive Agreement
12:00am
8-K
5olk10o
1 Mar 18
NewLink Genetics Reports Fourth Quarter, Year-End 2017 Financial Results and Provides Update for Indoximod Programs
12:00am
8-K
0rt b08k4srg5b
8 Jan 18
Other Events
12:00am
8-K
157sz6t5zh1rlq8x
11 Dec 17
Entry into a Material Definitive Agreement
12:00am
8-K
o56uydhn9p2o1bvr481q
20 Nov 17
NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children
12:00am
8-K
wiknccpw9x
14 Nov 17
NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer
12:00am
8-K
oxfrd6c
2 Nov 17
NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program
12:00am
8-K
r1yt3jl ahf93iu
30 Oct 17
NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod
12:00am
8-K
l0ato umk
4 Oct 17
Other Events
12:00am
8-K
60ayx3n
3 Oct 17
NewLink Genetics Announces Proposed Public Offering of Common Stock
12:00am
8-K
7my8uafo
25 Sep 17
NewLink Genetics Announces Clinical Collaboration to Evaluate IO-Based Combination Therapies in Pancreatic Cancer
12:00am
8-K
54w cfv8k
7 Sep 17
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma
12:00am
8-K
r4uzj5vz9w
28 Jul 17
NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program
12:00am
8-K
ihyvg mrcn1q
27 Jul 17
NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802
12:00am